These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 25732053)

  • 1. Progressive supranuclear palsy: what do we know about it?
    Long L; Cai XD; Wei XB; Liao JC; Xu YQ; Gao HM; Chen XH; Wang Q
    Curr Med Chem; 2015; 22(10):1182-93. PubMed ID: 25732053
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cerebral Tau Deposition in Comorbid Progressive Supranuclear Palsy and Amyotrophic Lateral Sclerosis: An [18F]-Flortaucipir and 7T MRI Study.
    Cheong I; Du Y; Smith G; Hua J; Li X; Pantelyat A
    Neurodegener Dis; 2023; 23(3-4):35-42. PubMed ID: 38527450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The MAPT p.E342K and p.R406W mutations are associated with progressive supranuclear palsy with atypical features.
    Badihian N; Ali F; Botha H; Savica R; Machulda MM; Clark HM; Stierwalt JAG; Pham NTT; Baker MC; Rademakers R; Lowe V; Whitwell JL; Josephs KA
    Parkinsonism Relat Disord; 2024 Feb; 119():105962. PubMed ID: 38134678
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progressive supranuclear palsy: Neuropathology, clinical presentation, diagnostic challenges, management, and emerging therapies.
    DeRosier F; Hibbs C; Alessi K; Padda I; Rodriguez J; Pradeep S; Parmar MS
    Dis Mon; 2024 Jun; ():101753. PubMed ID: 38908985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetics of Progressive Supranuclear Palsy: A Review.
    Wen Y; Zhou Y; Jiao B; Shen L
    J Parkinsons Dis; 2021; 11(1):93-105. PubMed ID: 33104043
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Automatic covariance pattern analysis outperforms visual reading of
    Buchert R; Wegner F; Huppertz HJ; Berding G; Brendel M; Apostolova I; Buhmann C; Dierks A; Katzdobler S; Klietz M; Levin J; Mahmoudi N; Rinscheid A; Rogozinski S; Rumpf JJ; Schneider C; Stöcklein S; Spetsieris PG; Eidelberg D; Wattjes MP; Sabri O; Barthel H; Höglinger G;
    Mov Disord; 2023 Oct; 38(10):1901-1913. PubMed ID: 37655363
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A case of atypical progressive supranuclear palsy.
    Spaccavento S; Del Prete M; Craca A; Loverre A
    Clin Interv Aging; 2014; 9():31-9. PubMed ID: 24368882
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radiological biomarkers for diagnosis in PSP: Where are we and where do we need to be?
    Whitwell JL; Höglinger GU; Antonini A; Bordelon Y; Boxer AL; Colosimo C; van Eimeren T; Golbe LI; Kassubek J; Kurz C; Litvan I; Pantelyat A; Rabinovici G; Respondek G; Rominger A; Rowe JB; Stamelou M; Josephs KA;
    Mov Disord; 2017 Jul; 32(7):955-971. PubMed ID: 28500751
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New Perspectives in Radiological and Radiopharmaceutical Hybrid Imaging in Progressive Supranuclear Palsy: A Systematic Review.
    Strobel J; Müller HP; Ludolph AC; Beer AJ; Sollmann N; Kassubek J
    Cells; 2023 Dec; 12(24):. PubMed ID: 38132096
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Uncovering distinct progression patterns of tau deposition in progressive supranuclear palsy using [
    Hong J; Lu J; Liu F; Wang M; Li X; Clement C; Lopes L; Brendel M; Rominger A; Yen TC; Guan Y; Tian M; Wang J; Zuo C; Shi K;
    EBioMedicine; 2023 Nov; 97():104835. PubMed ID: 37839135
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches.
    Boxer AL; Yu JT; Golbe LI; Litvan I; Lang AE; Höglinger GU
    Lancet Neurol; 2017 Jul; 16(7):552-563. PubMed ID: 28653647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Omics profile of iPSC-derived astrocytes from Progressive Supranuclear Palsy (PSP) patients.
    Ravagnani FG; Valerio HP; Maués JHS; de Oliveira AN; Puga RD; Griesi-Oliveira K; Picosse FR; Ferraz HB; Catharino RR; Ronsein GE; de Carvalho Aguiar P
    Parkinsonism Relat Disord; 2023 Nov; 116():105847. PubMed ID: 37844348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel
    Li H; Li Q; Weng Q; Cui R; Yen TC; Li Y
    Front Neurol; 2024; 15():1372507. PubMed ID: 38708005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Late-life mood disorder as the initial presentation of progressive supranuclear palsy: A case series.
    Ichijo K; Takahata K; Kurose S; Watanabe T; Nagase Y; Endo H; Tagai K; Ishitobi M; Higuchi M
    PCN Rep; 2024 Mar; 3(1):e178. PubMed ID: 38868471
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heavy metals contaminating the environment of a progressive supranuclear palsy cluster induce tau accumulation and cell death in cultured neurons.
    Alquezar C; Felix JB; McCandlish E; Buckley BT; Caparros-Lefebvre D; Karch CM; Golbe LI; Kao AW
    Sci Rep; 2020 Jan; 10(1):569. PubMed ID: 31953414
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Loss of Mickey Mouse Ears' Sign in Progressive Supranuclear Palsy.
    Chow TK; Ma KM
    Clin Nucl Med; 2024 Jun; 49(6):551-553. PubMed ID: 38598736
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation between clinical and neuropathological subtypes of progressive supranuclear palsy.
    Koizumi R; Akagi A; Riku Y; Miyahara H; Sone J; Tanaka F; Yoshida M; Iwasaki Y
    Parkinsonism Relat Disord; 2024 Mar; ():106076. PubMed ID: 38494398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progressive supranuclear palsy: Advances in diagnosis and management.
    Coughlin DG; Litvan I
    Parkinsonism Relat Disord; 2020 Apr; 73():105-116. PubMed ID: 32487421
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacotherapies for the Treatment of Progressive Supranuclear Palsy: A Narrative Review.
    Dunning EE; Decourt B; Zawia NH; Shill HA; Sabbagh MN
    Neurol Ther; 2024 May; ():. PubMed ID: 38743312
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.